Large Molecule

Pfizer Considers Sale of Acquired Hospira Devices Biz

Source: Bloomberg

Jan 14, 2016

Pfizer is considering a sale of the pumps and devices business it acquired in last year’s purchase of Hospira, says Bloomberg sources.

Sources say the NY-based drugmaker is in the early stages of a deal that could be worth around $2 billion.

Last February, Pfizer announced that it had acquired Hospira, the world’s leading provider of injectable drugs and infusion technologies and a global leader in biosimilars, for approximately $17 billion.

According to analysts, selling the devices business would leave Pfizer a more pure-play drugs unit for a possible spinoff.

Read the Bloomberg article